Vascodagama Online Journal

Corneal Endothelial Dystrophy Market to Observe Impressive Growth by 2030 | Key Companies includes Aerie Pharmaceuticals, Price Vision, Kowa Company, Trefoil Therapeutics and Others

 Breaking News
  • No posts were found

Corneal Endothelial Dystrophy Market to Observe Impressive Growth by 2030 | Key Companies includes Aerie Pharmaceuticals, Price Vision, Kowa Company, Trefoil Therapeutics and Others

October 08
01:09 2021
Corneal Endothelial Dystrophy Market to Observe Impressive Growth by 2030 | Key Companies includes Aerie Pharmaceuticals, Price Vision, Kowa Company, Trefoil Therapeutics and Others
Delveinsight Business Research LLP
DelveInsight’s “Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Corneal Endothelial Dystrophy Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Corneal Endothelial Dystrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

Corneal Endothelial Dystrophy Market

 

Corneal Endothelial Dystrophy: An Overview

According to Corneal dystrophies are a group of rare genetic, often progressive, eye disorders in which abnormal material often accumulates in the clear (transparent) outer layer of the eye (cornea). There are more than 20 different types of corneal dystrophies which are generally grouped into three categories. The presence of corneal endothelial dystrophy may be found incidentally during a routine eye examination. Some specific corneal dystrophies can be diagnosed with molecular genetic tests even before symptoms develop.

Corneal Endothelial Dystrophy Market Key Facts

  • Corneal dystrophies can affect individuals of any age. Because some individuals do not have symptoms (asymptomatic), determining the true frequency of these disorders in the general population is difficult.

  • Through various secondary studies, it can be concluded Corneal dystrophies affect women and men in equal numbers, except for Fuchs corneal dystrophy which affects women about four times as often as men.

  • According to the study by Moshirfar et al., (2020) in the United States, less than 0.01% of Americans are affected by corneal dystrophy (CD). It also stated the findings of another study which showed that around 530 persons out of a million in the United States have an endothelial-type CD.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/corneal-endothelial-dystrophy-market

Key Benefits of Corneal Endothelial Dystrophy Market Report

  • The report provides an in-depth analysis of Corneal Endothelial Dystrophy Market Size and Share till 2030 in the seven major markets.

  • The report will help in developing business strategies by understanding the Corneal Endothelial Dystrophy Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.

  • It covers Corneal Endothelial Dystrophy current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.

  • The report provides a detailed assessment of the Corneal Endothelial Dystrophy market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Corneal Endothelial Dystrophy Market 

Corneal Endothelial Dystrophy market size is expected to increase during the forecast period owing to the rise in the number of prevalent cases in the 7MM.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Corneal Endothelial Dystrophy market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Corneal Endothelial Dystrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Corneal Endothelial Dystrophy Epidemiology

The epidemiology section covers insights about the historical and current Corneal Endothelial Dystrophy patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Corneal Endothelial Dystrophy Epidemiology Segmentation

  • Prevalent Population of Corneal Dystrophy

  • Prevalent Population of Corneal Endothelial Dystrophy

  • Diagnosed and Treatable Cases of Corneal Endothelial Dystrophy

  • Type-specific Prevalent Population of Corneal Endothelial Dystrophy

Corneal Endothelial Dystrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Corneal Endothelial Dystrophy market or expected to get launched in the market during the study period. The analysis covers Corneal Endothelial Dystrophy market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Corneal Endothelial Dystrophy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

The dynamics of the Corneal Endothelial Dystrophy market is anticipated to change in the coming years owing to the improvement in the research and development undertaking. There are few key players involved in developing the therapies for Corneal Endothelial Dystrophy which are expected to launch during the forecast period.

The key companies in the Corneal Endothelial Dystrophy market include:

  • Aerie Pharmaceuticals

  • Price Vision Group

  • Kowa Company

  • Trefoil Therapeutics

And others.

Corneal Endothelial Dystrophy Therapies covered in the report include 

  • Rhopressa

  • Glanatec

  • TTHX1114

And many others.

Request for Sample @ Corneal Endothelial Dystrophy Therapeutics Market Assessment

Table of Content

1. Key Insights

2. Executive Summary 

3. Corneal Endothelial Dystrophy Competitive Intelligence Analysis

4. Corneal Endothelial Dystrophy Market Overview at a Glance

5. Corneal Endothelial Dystrophy Disease Background and Overview

6. Corneal Endothelial Dystrophy Patient Journey

7. Corneal Endothelial Dystrophy Epidemiology and Patient Population

8. Corneal Endothelial Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Corneal Endothelial Dystrophy Unmet Needs

10. Key Endpoints of Corneal Endothelial Dystrophy Treatment

11. Corneal Endothelial Dystrophy Marketed Products

12. Corneal Endothelial Dystrophy Emerging Therapies

13. Corneal Endothelial Dystrophy Seven Major Market Analysis

14. Attribute Analysis

15. Corneal Endothelial Dystrophy Market Outlook (7 major markets)

16. Corneal Endothelial Dystrophy Access and Reimbursement Overview

17. KOL Views on the Corneal Endothelial Dystrophy Market.

18. Corneal Endothelial Dystrophy Market Drivers

19. Corneal Endothelial Dystrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/corneal-endothelial-dystrophy-market

Trending Healthcare Blogs
West Syndrome Market Growth Analysis
As per DelveInsight, the West syndrome market is expected to increase at a CAGR of 5.8% in the 7MM during the study period (2018–30). The treatment of West Syndrome is challenging with available therapy options in the market. To address the prevailing unmet needs, pharma companies such as GW Pharmaceuticals plc, BioPharm Solutions, Insys Therapeutics, and others are developing therapies to bridge the treatment gap. Read More: West Syndrome Treatment Market

Get in touch with our Business executive for Competitive Intelligence Services

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/